Effect of a MUC5AC Antibody (NPC-1C) Administered with Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients with Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial
Brandon M. Huffman, Atrayee Basu Mallick, Nora K. Horick, Andrea Wang-Gillam, Peter Joel Hosein, Michael A. Morse, Muhammad Shaalan Beg, Janet E. Murphy, Sharon Mavroukakis, Anjum Zaki, Benjamin L. Schlechter, Hanna Sanoff, Christopher Manz, Brian M. Wolpin, Philip Arlen, Jill Lacy, James M. Cleary
Dive into the research topics of 'Effect of a MUC5AC Antibody (NPC-1C) Administered with Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients with Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial'. Together they form a unique fingerprint.